Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Insurance
    • Humana, private equity...

    Humana, private equity firms buy Kindred Healthcare for 810 million dollars

    Written by Ruby Khatun Khatun Published On 2017-12-22T09:15:26+05:30  |  Updated On 22 Dec 2017 9:15 AM IST
    Humana, private equity firms buy Kindred Healthcare for 810 million dollars

    U.S. health insurer Humana Inc and two private equity firms agreed to buy home healthcare and long-term care operator Kindred Healthcare Inc for about $810 million, the latest expansion by an American health insurer into patient care.


    Humana, TPG Capital, and Welsh, Carson, Anderson & Stowe will pay $9 per share in cash. They said that, with debt and other costs, they are paying about $4 billion (3 billion pounds) for the company.


    The companies, both based in Louisville, Kentucky, plan to split Kindred into two separate companies: a larger one that focuses on home healthcare and the other focused on long-term acute care and rehabilitation.


    Humana, the fourth largest U.S. health insurer, will pay $800 million in cash for Kindred shares and to cover other costs. That will give it a 40 percent stake in Kindred at Home, which will employ the 40,000 Kindred caregivers who serve about 130,000 patients daily. It will not have a stake in the second Kindred unit.


    Humana’s insurance business is focused on individuals in the U.S. government’s Medicare program for the elderly and disabled. The acquisition builds on Humana’s focus on using health providers in members’ homes to improve health outcomes and save costs.


    The deal comes after competitors Aetna Inc. and UnitedHealth Group Inc announced deals that will expand the reach of those insurers into healthcare services in locations and sites that charge less than hospitals.


    Soaring healthcare costs have been a national issue, and the federal government has been restricting its spending for health, putting pressure on insurers.


    Wall Street analysts said the Kindred deal, which had been reported on Sunday based on unnamed sources, would not end speculation that Humana itself could be a takeover target in the current healthcare consolidation wave.


    Earlier this month, Aetna announced a $69 billion deal to be bought by CVS Health Corp, fueling Wall Street interest in how smaller rivals Humana and Cigna Corp will compete.


    Humana agreed two years ago to be bought by Aetna but that deal was blocked by federal antitrust regulators who said that it would be anticompetitive. A similar deal by Anthem Inc. to buy Cigna was also blocked at the time.


    The company has the right to purchase the 60 percent stake in Kindred at Home owned by the private equity firms at the end of the third year. The deal is expected to close in the summer of 2018.


    Humana said it expects the deal to “slightly” add to earnings per share in 2019 and beyond.


    Morgan Stanley is the lead adviser to Humana and the private equity firms and JP Morgan is also a lead adviser to the private equity firms. TripleTree and law firm Fried, Frank, Harris Shriver & Jacobson advised Humana. Evercore did a fairness opinion for Humana’s board of directors. Barclays and Guggenheim Securities are financial advisers to Kindred and Cleary Gottlieb Steen & Hamilton LLP is its legal counsel.


    Kindred shares were trading at $8.98 per share, down 5 percent, having gained on Monday on Sunday reports of the deal. The $9-per-share price was a 4.7 percent premium over the stock’s Friday close.


    Humana shares were down 1 percent, or $2.28, at $244.10.




    (Reporting by Caroline Humer in New York and Manas Mishra in Bengaluru; Editing by Frances Kerry and Jonathan Oatis)



    AetnabuycignaHealth insurerHumanaKindredKindred Healthcareprivate equity firmsTPG capitalWelsh
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok